Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas

Diseases of the Esophagus

Volumn 20, Issue 1, 2007, Pages 9-11

  Pühringer Oppermann, Franziska A ^a,c   Stein, H J ^a   Sarbia, M ^b  

^a University Hospital Salzburg   (Austria)

^b SANA KLINIKUM OFFENBACH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Denaturing high pressure liquid chromatography; Epidermal growth factor receptor; Esophage aladenocarcinomas; Gefitinib; Mutations

Indexed keywords

ADENINE NUCLEOTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GUANINE NUCLEOTIDE; PROTEIN TYROSINE KINASE;

ARTICLE; BARRETT ESOPHAGUS; CODON; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DRUG SENSITIVITY; ESOPHAGEAL ADENOCARCINOMA; EXON; FEMALE; GENE MUTATION; GENETIC CODE; GENOTYPE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; PROTEIN DOMAIN; WILD TYPE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; BARRETT ESOPHAGUS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CODON; ESOPHAGEAL NEOPLASMS; EXONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33846218549     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2007.00630.x     Document Type: Article

References (15)

1. Harari P M. Epidermal Growth factor receptor inhibition strategies in oncology. Endocrine-Related. Cancer 2004; 11: 689-708.
2. Nicholson R I, Gee J M, Harper M E. EGFR and cancer prognosis. Eur J Cancer 2001; 37: S9-15.
3. Herbst R S, Fukuoka M, Baselga J. Gefitinib-a novel targeted approach to treating cancer. Nat Rev Cancer 2004; 4: 956-65.
4. Paez J G, Janne P A, Lee J C et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
5. Lynch T J, Bell D W, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
6. Lee J W, Soung Y H, Kim S Y et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 2005a; 11: 2879-82.
7. Lee J W, Soung Y H, Kim S Y et al. Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer. Int J Cancer 2005b; 113: 510-11.
8. Endo K, Konishi A, Sasaki H et al. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 2005; 50: 375-84.
9. Sarbia M, Arjumand J, Wolter M, Reifenberger G, Heep H, Gabbert H E. Frequent c-myc amplification in high-grade dysplasia and adenocarcinoma in Barrett's esophagus. Am J Clin Path 2001; 115: 835-40.
10. Keller G, Hartmann A, Mueller J, Hoefler H. Denaturing High Pressure Liquid Chromatography (DHPLC) for the analysis of somatic p53 mutations. Lab Invest 2001; 81: 1735-7.
11. Sobin L H, Wittekind C H (eds). UICC: TNM Classification of Malignant Tumours, 6th edn. New York: Wiley & Sons, 2002.
12. Su M C, Lien H C, Jeng Y M. Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma. Cancer Lett 2005; 224: 117-21.
13. al-Kasspooles M, Moore J H, Orringer M B, Beer D G. Amplification and over-expression of the EGFR and erbB-2 genes in human oesophageal adenocarcinomas. Int J Cancer 1993; 54: 213-9.
14. Hirata A, Ogawa S, Kometani T et.al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002; 62: 2554-60.
15. Barnes C J, Bagheri-Yarmand R, Mandal M et.al. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther 2003; 2: 345-51.